{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "from bs4 import BeautifulSoup\n",
    "import pandas as pd\n",
    "import re"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "url = \"https://psychedelicalpha.com/data/psychedelic-drug-development-tracker\"\n",
    "response = requests.get(url)"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "En este código busco hacer un df de los textos del pop up de cada lab"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "soup = BeautifulSoup(response.content, 'html.parser')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "div_elements = soup.find_all('div', class_='uael-content')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "text_list = []\n",
    "for div_element in div_elements:\n",
    "    p_element = div_element.find('p')\n",
    "    text = p_element.get_text(strip=True)\n",
    "    text_list.append(text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['MAPS has completed conducting two Phase 3 trials investigating MDMA-assisted psychotherapy as a potential treatment of post-traumatic stress disorder after receiving Breakthrough Therapy Status from the FDA. The first Phase III study (MAPP1) ispublished hereand a second Phase III study (MAPP2) was announced as completed in December 2022 (NCT04077437).',\n",
       " \"COMP360 is a psilocybin formulation currently being evaluated for potential use in treatment-resistant depression, after receiving Breakthrough Therapy Status from the FDA. Compass' Phase 3 program is composed of three clinical trials, two pivotal trials (known as COMP 005 and COMP 006) and one long-term follow-up, and is expected to commence by the end of 2022. More details about COMP005 can be found in the clinical trial registration link below. To learn more about the design of the Phase 3 studies, seePsychedelic Alpha Bulletin #120.\",\n",
       " 'Awakn is set to evaluate ketamine-assisted psychotherapy in a Phase 3 trial for the treatment of alcohol use disorder. Results from the Phase 2 trial can befound here.',\n",
       " 'GH001 is an inhaled formulation of 5-MeO-DMT, a short-acting psychedelic. GH001 is set to be evaluated in a Phase 2b trial for potential use in treatment-resistant depression. More details about the Phase 2b study can be found in the clinical trial registration link below. A combined Phase I/II study investigating GH001 for potential use in treatment-resistant depression was completed in 2021. The results of a Phase I study of GH001 werepublished here.',\n",
       " \"MM-120 is a formulation of LSD being evaluated in a Phase 2b study as a potential treatment for generalized anxiety disorder. As part of a deal with University Hospital Basel's Liechti Lab, MindMed acquired the rights to a completed Phase 2 trial, which waspublished here.\",\n",
       " 'SYNP-101 is a synthetic form of psilocybin being developed by B.More. SYNP-101 is set to be evaluated in a Phase 2b trial as a potential treatment for alcohol use disorder. The results of an associated pilot trial can befound here.',\n",
       " 'APEX-52 is a low dose psilocybin formulation being evaluated in a Phase 2b study as a potential take home treatment for depression in veterans with PTSD.',\n",
       " \"PCN-101 is arketamine (or R-ketamine), an isomer of ketamine. PCN-101 was evaluated in a Phase II trial for potential use in treatment-resistant depression. More details about the study can be found in the clinical trial registration below. Perception Neuroscience is one of atai Life Sciences' drug development programs.\",\n",
       " 'GH001 is an inhaled formulation of 5-MeO-DMT, a short-acting psychedelic. GH001 is being evaluated in a Phase 2 trial in patients with bipolar II disorder and a current major depressive episode. More details about the Phase 2 study can be found in the clinical trial registration link below.',\n",
       " 'GH001 is an inhaled formulation of 5-MeO-DMT, a short-acting psychedelic. GH001 is being evaluated in a Phase 2 trial in patients with postpartum depression. More details about the Phase 2 study can be found in the clinical trial registration link below.',\n",
       " 'NM-1001 is a low dose psilocybin formulation set to be evaluated in a Phase 2a trial as a potential treatment for Fragile X Syndrome. Nova Mentis was granted orphan drug designation from the FDA and European Medicines Agency for the development of NM-1001. Results from preclinical studies on NM-1001 can befound here.',\n",
       " 'BPL-003 is an intranasal formulation of synthetic 5-MeO-DMT and is currently being evaluated in a Phase 2 study for treatment-resistant depression. More details about the study can be found in the clinical trial registration link below.',\n",
       " 'MM-110, also known as 18-MC or zolunicant, is a non-hallucinogenic ibogaine derivative. MM-110 intended for use in opioid withdrawal and as a potential treatment of opioid use disorder and is set to be evaluated in a Phase 2a trial. Details about a completed Phase 1 study can be found in the clinical trial registration link below.',\n",
       " 'MAPS is evaluating MDMA-assisted group therapy in a Phase 2 trial as a potential treatment for PTSD. More details about the study can be found in the clinical trial registration link below.',\n",
       " 'MAPS is evaluating MDMA-assisted psychotherapy in a Phase 2 study as a potential treatment for eating disorders (anorexia nervosa and binge eating disorder). More details about the study can be found in the clinical trial registration link below.',\n",
       " 'The Usona Institute is currently evaluating psilocybin-assisted therapy in a Phase 2 trial as a potential treatment for major depressive disorder, after receiving Breakthrough Therapy Status from the FDA. More details about the study can be found in the clinical trial registration link below.',\n",
       " 'TRP-8802 is an orally-delivered synthetic psilocybin formulation set to be evaluated in a Phase 2 trial as a potential treatment for fibromyalgia. More details about the trial can be found in the clinical trial registration link below.',\n",
       " 'COMP360 is a psilocybin formulation currently being evaluated in a Phase 2 trial for potential use in anorexia nervosa. More information about the study can be found in the clinical trial registration link below.',\n",
       " 'COMP360 is a psilocybin formulation currently being evaluated in a Phase II trial for potential use in post-traumatic stress disorder (PTSD). More details about the study can be found in the clinical trial registration link below.',\n",
       " 'Braxia is evaluating psilocybin-assisted therapy in a Phase II trial for potential use in treatment-resistant depression. More details about the trial can be found in the clinical trial registration link below.',\n",
       " 'SPRAVATO is an intranasal esketamine formulation being evaluated in a Phase 2 study as a potential treatment for symptoms of major depressive disorder including suicidal ideation, in participants 12 to less than 18 years of age. SPRAVATO has already received FDA approval for use in adults with treatment-resistant depression or acute suicidal ideation and behaviour in major depressive disorder. Please see theSPRAVATO labelfor more information.',\n",
       " 'SLS-002 is an intranasal racemic ketamine product currently being evaluated in a Phase 2 trial as a potential treatment for acute suicidal ideation and behaviour (ASIB) in major depressive disorder. More details about the ongoing trial can be found in the clinical trial registration link below.',\n",
       " \"As part of a deal with University Hospital Basel's Liechti Lab, MindMed has acquired the rights to an ongoing Phase II evaluating LSD as a potential treatment for cluster headaches. More details about the study can be found in the clinical trial registration link below.\",\n",
       " 'In partnership with Monash University, Incannex is evaluating psilocybin-assisted therapy in a Phase II trial as a potential treatment for generalized anxiety disorder. More details about the study can be found in the clinical trial registration link below.',\n",
       " 'CLE-100 is a formulation of oral esketamine currently being evaluated in a Phase 2 study as a potential treatment for major depressive disorder. More details about the trial can be found in the clinical trial registration link below.',\n",
       " 'Clairvoyant is evaluating psilocybin-assisted therapy in a Phase 2 trial as a potential treatment for alcohol use disorder. More details about the study can be found in the clinical trial registration link below.',\n",
       " 'SYNP-101 is a synthetic form of psilocybin being developed as a potential treatment for obsessive compulsive disorder. SYNP-101 is currently being evaluated in a Phase 2 trial. More details about an associated trial can be found in the clinical trial registration link below.',\n",
       " 'Psyence is set to evaluate psilocybin-assisted therapy in a Phase 2 study for the treatment of adjustment disorder due to an incurable cancer diagnosis in a palliative care context.',\n",
       " 'BPL-003 is an intranasal formulation of synthetic 5-MeO-DMT and is currently being evaluated in a Phase 2 study for alcohol use disorder. More details about the study can be found in the clinical trial registration link below.',\n",
       " \"Top-line results from Small Pharma's Phase IIa trial of DMT for MDDare now available.\",\n",
       " 'MM-120 is a formulation of LSD being evaluated in a Phase 2 trial as a potential treatment for attention deficit hyperactivity disorder (ADHD) in adults. More details about the trial can be found in the clinical trial registration link below.',\n",
       " 'CYB003 is an orally dissolving tablet formulation of an unknown deuterated psilocybin analog currently being evaluated in a Phase 1/2 trial for major depressive disorder. More details about the study can be found in the clinical trial registration below.',\n",
       " \"DMX-1002 is an ibogaine formulation set to be evaluated in a combined Phase I/II study as a potential treatment for opioid use disorder (specifically for medically-assisted detoxification). DemeRx is one of atai Life Sciences' drug development programs. More details about the Phase I/II study can be found in the clinical trial registration link below.\",\n",
       " 'ELE-001 is an intravenous (IV) formulation of psilocin, the active metabolite of psilocybin, being developed as a possible treatment for depression. ELE-001 was acquired by Beckley Psytech from Eleusis Therapeutics in October 2022, who had begun a Phase 1/2 trial. More details about the trial can be found in the clinical trial registration link below.',\n",
       " 'AP-188 is a sub-hallucinogenic, IV DMT formulation being developed as a possible treatment of ischemic stroke and for post-stroke rehabilitation. AP-188 is currently being evaluated in a Phase 1 trial.',\n",
       " 'BMND01 is a liquid inhaled formulation of DMT that was evaluated in a Phase 1 study. More details about the study can be found in the clinical trial registration link below.',\n",
       " 'MELOCIN is a naturally derived Psilocybe extract set to be evaluated in a Phase I trial. More details about the trial can be found in the clinical trial registration link below.',\n",
       " 'MM-402 is R(-)-MDMA, an isomer of MDMA, as a potential treatment for social anxiety associated with Autism Spectrum Disorder. R-MDMA is being evaluated in a Phase I trial comparing it S-MDMA and racemic MDMA (R/S MDMA). More details about the study can be found in the clinical trial registration link below.',\n",
       " 'MindMed is evaluating mescaline in a Phase I trial, though the intended indication(s) remains unclear. More details about the trial can be found in the clinical trial link below.',\n",
       " 'RE104 is isoprocin glutarate, a prodrug of 4-HO-DiPT. RE104 is currently being evaluated in a Phase 1 trial and is intended for use in postpartum depression. More details about the study can be found in the clinical trial registration link below.',\n",
       " 'NYPRG-101 is a non-hallucinogenic LSD analog, more commonly known as 2-Bromo-LSD or BOL-148. NYPRG-101 is currently in Phase I and is being evaluated as a potential treatment of cluster headaches.',\n",
       " 'GH002 is an injectable formulation of 5-MeO-DMT, a short-acting psychedelic. GH002 is set to be evaluated in a Phase 1 study.',\n",
       " 'MSP-1014 is a deuterated prodrug of psilocybin set to be evaluated in a Phase 1 study. MSP-1014 is intended as a potential treatment of major depressive disorder.',\n",
       " \"EmpathBio is developing EMP-01, an MDMA-derivative for use in entactogen-assisted psychotherapy to treat post-traumatic stress disorder. EMP-01 is currently being evaluated in a Phase 1 trial. More details about the study can be found in the clinical trial registration link below. EmpathBio is one of atai Life Sciences' drug development programs.\",\n",
       " 'SPL026 is a formulation of DMT being developed as a potential treatment for major depressive disorder. SPL026 is currently being evaluated in a Phase 1 study to compare the effects when administered intravenously (IV) or intramuscularly (IM). Small Pharma was granted an Innovation Passport Designation for SPL026 from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA). More details about the study can be found in the clinical trial registration link below.',\n",
       " 'SPL028 is a formulation of an unknown deuterated DMT molecule. SPL028 is currently being evaluated in a Phase 1 trial to compare the effects when administered intravenously (IV) or intramuscularly (IM).',\n",
       " 'VLS-01 is a formulation of DMT intended for potential use in treatment-resistant depression. VLS-01 is currently being evaluated in a Phase 1 trial to compare the effects when administered intravenously (IV) or buccally.',\n",
       " 'BMB-101 is an unknown 5-HT2C agonist being evaluated in a Phase 1 trial for potential use in Dravet Syndrome, opioid use disorder, and binge eating disorder. More details about the study can be found in the clinical trial registration link below.',\n",
       " \"Diamond Therapeutics' lead programme is the development of low-dose psilocybin for the potential treatment of undisclosed anxiety disorders. Diamond completed a Phase 1 trial in late 2022. Previously reported preclinical trial results can befound here.\",\n",
       " 'NYPRG-101 is a non-hallucinogenic LSD analog, more commonly known as 2-Bromo-LSD or BOL-148. NYPRG-101 is currently in Phase I and is being evaluated as a potential treatment of migraines.',\n",
       " 'Delix Therapeutics is developing a number of non-hallucinogenic psychedelic compounds, referred to as psychoplastogens, and is currently in the preclinical stage of development. Details about one of Delix Therapeutics\\' lead compounds \"DLX-7\" or Tabernanthalog (TBG), an ibogaine analog, werepublished hereandhere. Details about another compound, \"DLX-1\", also known as AAZ-A-154, werepublished here.',\n",
       " 'CYB003 is an orally dissolving tablet formulation of an unknown deuterated psilocybin analog currently in the preclinical stage of development, intended as a treatment for alcohol use disorder.',\n",
       " 'NYPRG-101 is a non-hallucinogenic LSD analog, more commonly known as 2-Bromo-LSD or BOL-148. NYPRG-101 is currently in the preclinical stage and is being evaluated as a potential treatment of both opioid and alcohol use disorder.',\n",
       " 'BB-106 is a ketamine formulation delivered subcutaneously via a wearable medical pump. BB-106 is currently in the preclinical stage and is being evaluated as a potential treatment of depression, as well as a variety of pain-related indications including post-operative pain, cancer pain, and Complex Regional Pain Syndrome.',\n",
       " 'Gilgamesh Pharmaceuticals is a preclinical biotechnology company developing several psychedelic-related medicines including:',\n",
       " 'Terran Biosciences is developing a number of unknown compounds to treat neurological and psychiatric indications, having acquired or licensed assets fromConcert Pharmaceuticals,Blumentech,Sanofi, andUniversity of Maryland, Baltimore.',\n",
       " 'Freedom Biosciences is in the preclinical stages of developing a combination therapy consisting of ketamine and an mTORC1 inhibitor (presumed to be rapamycin) for the treatment of major depressive disorder.',\n",
       " 'Mindset Pharma is currently in the preclinical stages of development for a number of compounds including MSP-2020 and MSP-2003, two unknown 5-HT2A agonists. Mindset Pharma is collaborating with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies.',\n",
       " 'AM-1002 is an unknown phenethylamine empathogen in the preclinical stage of development, intended for use in PTSD.',\n",
       " 'LPH-5 is an unknown 5-HT2A agonist currently in the preclinical stage and is being investigated for potential use in treatment-resistant depression. Lophora anticipates initiating a Phase I study of LPH-5 in 2023.',\n",
       " 'Psilera is currently in the preclinical stages of development for a number of compounds including:',\n",
       " 'Methylone.',\n",
       " 'Bright Minds has a number of 5-HT2A and combined 5-HT2A + 5-HT2C agonist molecules in the preclinical stage of development. The 5-HT2A compounds are being evaluated for use in depression and post-traumatic stress disorder. The combined 5-HT2A + 5-HT2C compounds are being evaluated for use in several chronic pain disorders, including cluster headaches and chemotherapy-induced peripheral neuropathy.',\n",
       " 'CaaMTech has a collaborative preclinical drug development program with the Designer Drug Research Unit at the National Institute on Drug Abuse Intramural Research Program to help determine which of their compounds are the most promising to proceed to human trials. These include, but are not limited to:',\n",
       " 'GH003 is an intranasal formulation of 5-MeO-DMT, a short-acting psychedelic. GH003 is currently in the preclinical stage for an unknown indication.',\n",
       " 'SPL029 is an unknown oral tryptamine 5-HT2A agonist molecule currently in the preclinical stage for an unknown indication.',\n",
       " 'NEO-001 is a synthetic form of psilocybin in the preclinical stages of development as a potential treatment for weight loss. NeonMind is currently conducting a preclinical trial with psilocybin as a potential treatment for obesity.',\n",
       " 'JOUR-5700 is a synthetic form of mescaline in the preclinical stages of development for the potential treatment of alcohol use disorder.',\n",
       " 'Tactogen has a number of unknown entactogen molecules in the preclinical stage of development.',\n",
       " 'BETR-001 is a non-hallucinogenic LSD derivative molecule, more commonly known as 2-Bromo-LSD or BOL-148. BETR-001 is currently in the preclinical stage and is being investigated for potential use in treatment-resistant depression, as well as migraines.',\n",
       " 'L-131.',\n",
       " 'SENS-01 is an unknown molecule currently in the preclinical stage of development, intended for use in anxiety and depression.',\n",
       " 'CMND-100 is a synthetic form of MEAI',\n",
       " 'TRP-8802 is an orally-delivered synthetic psilocybin formulation currently in the preclinical stage of being evaluated as a potential treatment for phantom limb pain.',\n",
       " 'LSR-1019 is a sublingual formulation of 5-MeO-DMT currently in the preclinical stage, intended for use in treatment-resistant depression.',\n",
       " 'PsiD+.',\n",
       " 'MSD-100.',\n",
       " 'PsyBio is developing a portfolio of tryptamine-derived candidates including psilocybin and norbaeocystin for a variety of undisclosed psychiatric conditions.',\n",
       " 'CaaMTech is a drug discovery company that aims to synthesize and characterize old and novel tryptamine compounds as well as optimize their various formulations. Their portfolio (see above for a partial list of published compounds) then undergoes preclinical assessment as part of a collaborative preclinical drug development program with the Designer Drug Research Unit at the National Institute on Drug Abuse Intramural Research Program.',\n",
       " 'PSY-01, PSY-02, PSY-05, PSY-06.',\n",
       " 'Discovery Center.',\n",
       " 'DMT and psilocybin (PsiM+, PsiK+, PsiH+, PsiX) discovery programs.',\n",
       " 'Mindset Pharma is currently in the discovery stages of development for a number of novel psychedelic compounds, including Family 3 (\"Low-potency, long-duration for micro-dosing\") and Family 4 (DMT/ 5-MeO-DMT-inspired compounds). Mindset Pharma is collaborating with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies.',\n",
       " 'Psylo is currently in the discovery stages of development for a number of compounds including:',\n",
       " 'MSD-101, MSD-102, MSD-103, MSD-104, MSD-105 Discovery Programs.',\n",
       " 'Lusaris is developing a portfolio of new compounds, including LSR-2000 and LSR-3000, intended for various neuropsychiatric and neurological disorders.',\n",
       " 'NCE discovery program.',\n",
       " 'Onsero is developing a portfolio of unknown 5-HT2A agonists for undisclosed neuropsychiatric indications.']"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "text_list"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "div_df = pd.DataFrame({'Text': text_list})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>MAPS has completed conducting two Phase 3 tria...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>COMP360 is a psilocybin formulation currently ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Awakn is set to evaluate ketamine-assisted psy...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>GH001 is an inhaled formulation of 5-MeO-DMT, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>MM-120 is a formulation of LSD being evaluated...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>Psylo is currently in the discovery stages of ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>MSD-101, MSD-102, MSD-103, MSD-104, MSD-105 Di...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>Lusaris is developing a portfolio of new compo...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>NCE discovery program.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>Onsero is developing a portfolio of unknown 5-...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>88 rows × 1 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                 Text\n",
       "0   MAPS has completed conducting two Phase 3 tria...\n",
       "1   COMP360 is a psilocybin formulation currently ...\n",
       "2   Awakn is set to evaluate ketamine-assisted psy...\n",
       "3   GH001 is an inhaled formulation of 5-MeO-DMT, ...\n",
       "4   MM-120 is a formulation of LSD being evaluated...\n",
       "..                                                ...\n",
       "83  Psylo is currently in the discovery stages of ...\n",
       "84  MSD-101, MSD-102, MSD-103, MSD-104, MSD-105 Di...\n",
       "85  Lusaris is developing a portfolio of new compo...\n",
       "86                             NCE discovery program.\n",
       "87  Onsero is developing a portfolio of unknown 5-...\n",
       "\n",
       "[88 rows x 1 columns]"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "div_df"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "WEB SCRAPPING PARA LOS NOMBRES DE LOS LABORATORIOS DESDE EL NOMBRE DE LAS IMÁGENES EN WEB"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "url = \"https://psychedelicalpha.com/data/psychedelic-drug-development-tracker\"\n",
    "response = requests.get(url)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                       Alt Text\n",
      "0                              \n",
      "1                      MAPS PBC\n",
      "2  Compass Pathways logo colour\n",
      "3           Awakn Life Sciences\n",
      "4                   GH Research\n"
     ]
    }
   ],
   "source": [
    "soup = BeautifulSoup(response.text, \"html.parser\")\n",
    "\n",
    "alt_text_list = []\n",
    "images = soup.find_all(\"img\")\n",
    "for image in images:\n",
    "    alt_text = image.get(\"alt\")\n",
    "    alt_text_list.append(alt_text)\n",
    "\n",
    "df_d = pd.DataFrame(alt_text_list, columns=[\"Alt Text\"])\n",
    "print(df_d.head())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "labs = df_d.iloc[:89,:]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Alt Text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>MAPS PBC</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Compass Pathways logo colour</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Awakn Life Sciences</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>GH Research</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>PSYLO Logo</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>Mindstate Design</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>Lusaris Therapeutics Logo</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>Beckley Psytech Logo</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>Onsero Logo</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>89 rows × 1 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                        Alt Text\n",
       "0                               \n",
       "1                       MAPS PBC\n",
       "2   Compass Pathways logo colour\n",
       "3            Awakn Life Sciences\n",
       "4                    GH Research\n",
       "..                           ...\n",
       "84                    PSYLO Logo\n",
       "85              Mindstate Design\n",
       "86     Lusaris Therapeutics Logo\n",
       "87          Beckley Psytech Logo\n",
       "88                   Onsero Logo\n",
       "\n",
       "[89 rows x 1 columns]"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "labs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\cynhe\\AppData\\Local\\Temp\\ipykernel_28864\\4092625311.py:1: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  labs['Alt Text'] = labs['Alt Text'].str.replace(r'logo?.\\w*', '', regex=True)\n"
     ]
    }
   ],
   "source": [
    "labs['Alt Text'] = labs['Alt Text'].str.replace(r'logo?.\\w*', '', regex=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Alt Text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>MAPS PBC</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Compass Pathways</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Awakn Life Sciences</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>GH Research</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>PSYLO Logo</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>Mindstate Design</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>Lusaris Therapeutics Logo</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>Beckley Psytech Logo</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>Onsero Logo</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>89 rows × 1 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                     Alt Text\n",
       "0                            \n",
       "1                    MAPS PBC\n",
       "2           Compass Pathways \n",
       "3         Awakn Life Sciences\n",
       "4                 GH Research\n",
       "..                        ...\n",
       "84                 PSYLO Logo\n",
       "85           Mindstate Design\n",
       "86  Lusaris Therapeutics Logo\n",
       "87       Beckley Psytech Logo\n",
       "88                Onsero Logo\n",
       "\n",
       "[89 rows x 1 columns]"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "labs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\cynhe\\AppData\\Local\\Temp\\ipykernel_28864\\506750647.py:1: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  labs['Alt Text'] = labs['Alt Text'].str.replace(r'Logo?.\\w*', '', regex=True)\n"
     ]
    }
   ],
   "source": [
    "labs['Alt Text'] = labs['Alt Text'].str.replace(r'Logo?.\\w*', '', regex=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "#labs.drop(index=labs.index[0], axis=0, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Alt Text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>MAPS PBC</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Compass Pathways</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Awakn Life Sciences</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>GH Research</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>PSYLO</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>Mindstate Design</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>Lusaris Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>Beckley Psytech</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>Onsero</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>89 rows × 1 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                 Alt Text\n",
       "0                        \n",
       "1                MAPS PBC\n",
       "2       Compass Pathways \n",
       "3     Awakn Life Sciences\n",
       "4             GH Research\n",
       "..                    ...\n",
       "84                 PSYLO \n",
       "85       Mindstate Design\n",
       "86  Lusaris Therapeutics \n",
       "87       Beckley Psytech \n",
       "88                Onsero \n",
       "\n",
       "[89 rows x 1 columns]"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "labs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\cynhe\\AppData\\Local\\Temp\\ipykernel_28864\\2737271472.py:1: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  labs['Alt Text'] = labs['Alt Text'].shift(-1)\n"
     ]
    }
   ],
   "source": [
    "labs['Alt Text'] = labs['Alt Text'].shift(-1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Alt Text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>MAPS PBC</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Compass Pathways</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Awakn Life Sciences</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>GH Research</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>MindMed</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>Mindstate Design</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>Lusaris Therapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>Beckley Psytech</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>Onsero</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>89 rows × 1 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                 Alt Text\n",
       "0                MAPS PBC\n",
       "1       Compass Pathways \n",
       "2     Awakn Life Sciences\n",
       "3             GH Research\n",
       "4                MindMed \n",
       "..                    ...\n",
       "84       Mindstate Design\n",
       "85  Lusaris Therapeutics \n",
       "86       Beckley Psytech \n",
       "87                Onsero \n",
       "88                    NaN\n",
       "\n",
       "[89 rows x 1 columns]"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "labs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "labs_div=pd.merge( labs, div_df, left_index=True, right_index=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Alt Text</th>\n",
       "      <th>Text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>MAPS PBC</td>\n",
       "      <td>MAPS has completed conducting two Phase 3 tria...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Compass Pathways</td>\n",
       "      <td>COMP360 is a psilocybin formulation currently ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Awakn Life Sciences</td>\n",
       "      <td>Awakn is set to evaluate ketamine-assisted psy...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>GH Research</td>\n",
       "      <td>GH001 is an inhaled formulation of 5-MeO-DMT, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>MindMed</td>\n",
       "      <td>MM-120 is a formulation of LSD being evaluated...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>PSYLO</td>\n",
       "      <td>Psylo is currently in the discovery stages of ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>Mindstate Design</td>\n",
       "      <td>MSD-101, MSD-102, MSD-103, MSD-104, MSD-105 Di...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>Lusaris Therapeutics</td>\n",
       "      <td>Lusaris is developing a portfolio of new compo...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>Beckley Psytech</td>\n",
       "      <td>NCE discovery program.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>Onsero</td>\n",
       "      <td>Onsero is developing a portfolio of unknown 5-...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>88 rows × 2 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                 Alt Text                                               Text\n",
       "0                MAPS PBC  MAPS has completed conducting two Phase 3 tria...\n",
       "1       Compass Pathways   COMP360 is a psilocybin formulation currently ...\n",
       "2     Awakn Life Sciences  Awakn is set to evaluate ketamine-assisted psy...\n",
       "3             GH Research  GH001 is an inhaled formulation of 5-MeO-DMT, ...\n",
       "4                MindMed   MM-120 is a formulation of LSD being evaluated...\n",
       "..                    ...                                                ...\n",
       "83                 PSYLO   Psylo is currently in the discovery stages of ...\n",
       "84       Mindstate Design  MSD-101, MSD-102, MSD-103, MSD-104, MSD-105 Di...\n",
       "85  Lusaris Therapeutics   Lusaris is developing a portfolio of new compo...\n",
       "86       Beckley Psytech                              NCE discovery program.\n",
       "87                Onsero   Onsero is developing a portfolio of unknown 5-...\n",
       "\n",
       "[88 rows x 2 columns]"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "labs_div"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "WEB SCRAPPING DEL TÍTULO DEL ESTUDIO"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "url3 = \"https://psychedelicalpha.com/data/psychedelic-drug-development-tracker\"\n",
    "response3 = requests.get(url)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "soup3 = BeautifulSoup(response.content, 'html.parser')\n",
    "p_elements3 = soup3.find_all('p', class_='elementor-heading-title elementor-size-default')\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[<p class=\"elementor-heading-title elementor-size-default\">Post-traumatic stress disorder (PTSD)  |  MDMA <span style=\"font-family: Montserrat, sans-serif; font-size: 14px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 500;\">| Phase 3</span></p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Treatment-resistant depression (TRD)  |  COMP360 (Psilocybin) <span style=\"font-family: Montserrat, sans-serif; font-size: 14px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 500;\">| Phase 3</span></p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Alcohol use disorder (AUD)  |  Ketamine <span style=\"font-family: Montserrat, sans-serif; font-size: 14px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 500;\">| Phase 3</span></p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\"><span style=\"font-family: Montserrat, sans-serif; font-size: 14px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 500;\">Treatment-resistant depression (TRD)</span> | GH001 (5-MeO-DMT)  | Phase 2b</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Generalized Anxiety Disorder (GAD)  | MM-120 (LSD)  | Phase 2b</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Alcohol Use Disorder (AUD)  |  SYNP-101 (Psilocybin)  | Phase 2b</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\"><span style=\"font-family: Montserrat, sans-serif; font-size: 14px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 500;\">Post-traumatic stress disorder (PTSD)</span>  | APEX-25 (Psilocybin)  | Phase 2b</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\"><span style=\"font-family: Montserrat, sans-serif; font-size: 14px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 500;\">Treatment-resistant depression (TRD)</span>  |  PCN-101 (R-ketamine)  | Phase 2 (Complete)</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Bipolar Disorder II (BDII)  |  GH001 (5-MeO-DMT)  | Phase 2</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Postpartum Depression (PPD)  |  GH001 (5-MeO-DMT)  | Phase 2</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Fragile X Syndrome  |  NM-1001 (Psilocybin)  | Phase 2a</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\"><span style=\"font-family: Montserrat, sans-serif; font-size: 14px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 500;\">Treatment-resistant depression (TRD)</span> |  BPL-003 (5-MeO-DMT)  | Phase 2</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Opioid Withdrawal  | MM-110 (18-MC)  | Phase 2a</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\"><span style=\"font-family: Montserrat, sans-serif; font-size: 14px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 500;\">Post-traumatic stress disorder (PTSD)</span> |  MDMA  | Phase 2</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Anorexia nervosa &amp; Binge eating disorder |  MDMA  | Phase 2</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Major Depressive Disorder (MDD)  |  Psilocybin  | Phase 2</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Fibromyalgia  |  TRP-8802 (Psilocybin)  | Phase 2a</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Anorexia Nervosa  |  COMP360 (Psilocybin)  | Phase 2</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\"><span style=\"font-family: Montserrat, sans-serif; font-size: 14px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 500;\">Post-traumatic stress disorder (PTSD)</span>  |  COMP360 (Psilocybin)  | Phase 2</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\"><span style=\"font-family: Montserrat, sans-serif; font-size: 14px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 500;\">Treatment-resistant depression (TRD)</span>  |  Psilocybin  | Phase 2</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Major Depressive Disorder (MDD)  | Spravato (Esketamine)  | Phase 2</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Acute Suicidal Ideation and Behaviour  (ASIB)  |  SLS-002 (Ketamine)  | Phase 2</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Cluster Headaches  |  LSD | Phase 2</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Generalized Anxiety Disorder (GAD)  |  Psilocybin  | Phase 2</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Major Depressive Disorder (MDD)  |  CLE-100 (Esketamine)  | Phase 2</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Alcohol Use Disorder (AUD) |  Psilocybin  | Phase 2</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Obsessive Compulsive Disorder (OCD) |  SYNP-101 (Psilocybin)  | Phase 2</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Adjustment Disorder  |  Psilocybin  | Phase 2</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Alcohol Use Disorder (AUD)  |  BPL-003 (5-MeO-DMT)  | Phase 2</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Major Depressive Disorder (MDD) |  SPL026 (DMT)  | Phase 2a (Completed)</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Attention Deficit Disorder (ADHD)  |  MM120 (LSD)  | Phase 2a</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Major Depressive Disorder (MDD)  |  CYB003 (Deuterated Psilocybin Analog)  | Phase 1/2</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Opiate Withdrawal Syndrome  |  DMX-1002 (Ibogaine)  | Phase 1/2</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Major Depressive Disorder (MDD)  |  ELE-101 (Psilocin)  | Phase 1/2</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Ischemic Stroke  |  AP-188 (DMT)  | Phase 1</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Healthy Volunteers |  BMND01 (DMT)  | Phase 1</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Healthy Volunteers  |  Psilocybin  | Phase 1</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Autism Spectrum Disorder (ASD)  |  MM-402 (R(-)-MDMA) | Phase 1</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Healthy Volunteers  |  Mescaline  | Phase 1</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Healthy Volunteers  |  RE104 (4-HO-DiPT; Isoprocin Glutarate)  | Phase 1</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Cluster Headaches |  NYPRG-101 (BOL-148)  | Phase 1</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Healthy Volunteers  |  GH002 (5-MeO-DMT)  | Phase 1</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Major Depressive Disorder (MDD)  |  MSP-1014 (Deuterated Psilocybin Prodrug)  | Phase 1</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\"><span style=\"font-variant-ligatures: normal; font-variant-caps: normal; font-family: Montserrat, sans-serif; font-size: 14px; font-style: normal; font-weight: 500;\">Post-traumatic stress disorder (PTSD)</span><span style=\"font-family: Montserrat, sans-serif; font-size: 14px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 500;\"> </span>  |  EMP-01 (MDMA Derivative)  | Phase 1</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Major Depressive Disorder (MDD)  |  SPL029 (DMT)  | Phase 1</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Healthy Volunteers  |  SPL028 (Deuterated DMT)  | Phase 1</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\"><span style=\"font-variant-ligatures: normal; font-variant-caps: normal; font-family: Montserrat, sans-serif; font-size: 14px; font-style: normal; font-weight: 500;\">Treatment-resistant depression (TRD)</span><span style=\"font-family: Montserrat, sans-serif; font-size: 14px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 500;\"> </span>  |  VLS-01 (DMT)  | Phase 1</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Healthy Volunteers  |  BMB-101 (5-HT2C Agonist)  | Phase 1</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Anxiety Disorders  |  Psilocybin  | Phase 1</p>,\n",
       " <p class=\"elementor-heading-title elementor-size-default\">Migraines  |  NYPRG-101 (BOL-148)  | Phase 1</p>]"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "p_elements3"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "text_list3=[]\n",
    "for p_element3 in p_elements3:\n",
    "    text_ = p_element3.get_text(strip=True)\n",
    "    text_list3.append(text_)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Post-traumatic stress disorder (PTSD)  |  MDMA| Phase 3',\n",
       " 'Treatment-resistant depression (TRD)  |  COMP360 (Psilocybin)| Phase 3',\n",
       " 'Alcohol use disorder (AUD)  |  Ketamine| Phase 3',\n",
       " 'Treatment-resistant depression (TRD)| GH001 (5-MeO-DMT)  | Phase 2b',\n",
       " 'Generalized Anxiety Disorder (GAD)  | MM-120 (LSD)  | Phase 2b',\n",
       " 'Alcohol Use Disorder (AUD)  |  SYNP-101 (Psilocybin)  | Phase 2b',\n",
       " 'Post-traumatic stress disorder (PTSD)| APEX-25 (Psilocybin)  | Phase 2b',\n",
       " 'Treatment-resistant depression (TRD)|  PCN-101 (R-ketamine)  | Phase 2 (Complete)',\n",
       " 'Bipolar Disorder II (BDII)  |  GH001 (5-MeO-DMT)  | Phase 2',\n",
       " 'Postpartum Depression (PPD)  |  GH001 (5-MeO-DMT)  | Phase 2',\n",
       " 'Fragile X Syndrome  |  NM-1001 (Psilocybin)  | Phase 2a',\n",
       " 'Treatment-resistant depression (TRD)|  BPL-003 (5-MeO-DMT)  | Phase 2',\n",
       " 'Opioid Withdrawal  | MM-110 (18-MC)  | Phase 2a',\n",
       " 'Post-traumatic stress disorder (PTSD)|  MDMA  | Phase 2',\n",
       " 'Anorexia nervosa & Binge eating disorder |  MDMA  | Phase 2',\n",
       " 'Major Depressive Disorder (MDD)  |  Psilocybin  | Phase 2',\n",
       " 'Fibromyalgia  |  TRP-8802 (Psilocybin)  | Phase 2a',\n",
       " 'Anorexia Nervosa  |  COMP360 (Psilocybin)  | Phase 2',\n",
       " 'Post-traumatic stress disorder (PTSD)|  COMP360 (Psilocybin)  | Phase 2',\n",
       " 'Treatment-resistant depression (TRD)|  Psilocybin  | Phase 2',\n",
       " 'Major Depressive Disorder (MDD)  | Spravato (Esketamine)  | Phase 2',\n",
       " 'Acute Suicidal Ideation and Behaviour  (ASIB)  |  SLS-002 (Ketamine)  | Phase 2',\n",
       " 'Cluster Headaches  |  LSD | Phase 2',\n",
       " 'Generalized Anxiety Disorder (GAD)  |  Psilocybin  | Phase 2',\n",
       " 'Major Depressive Disorder (MDD)  |  CLE-100 (Esketamine)  | Phase 2',\n",
       " 'Alcohol Use Disorder (AUD) |  Psilocybin  | Phase 2',\n",
       " 'Obsessive Compulsive Disorder (OCD) |  SYNP-101 (Psilocybin)  | Phase 2',\n",
       " 'Adjustment Disorder  |  Psilocybin  | Phase 2',\n",
       " 'Alcohol Use Disorder (AUD)  |  BPL-003 (5-MeO-DMT)  | Phase 2',\n",
       " 'Major Depressive Disorder (MDD) |  SPL026 (DMT)  | Phase 2a (Completed)',\n",
       " 'Attention Deficit Disorder (ADHD)  |  MM120 (LSD)  | Phase 2a',\n",
       " 'Major Depressive Disorder (MDD)  |  CYB003 (Deuterated Psilocybin Analog)  | Phase 1/2',\n",
       " 'Opiate Withdrawal Syndrome  |  DMX-1002 (Ibogaine)  | Phase 1/2',\n",
       " 'Major Depressive Disorder (MDD)  |  ELE-101 (Psilocin)  | Phase 1/2',\n",
       " 'Ischemic Stroke  |  AP-188 (DMT)  | Phase 1',\n",
       " 'Healthy Volunteers |  BMND01 (DMT)  | Phase 1',\n",
       " 'Healthy Volunteers  |  Psilocybin  | Phase 1',\n",
       " 'Autism Spectrum Disorder (ASD)  |  MM-402 (R(-)-MDMA) | Phase 1',\n",
       " 'Healthy Volunteers  |  Mescaline  | Phase 1',\n",
       " 'Healthy Volunteers  |  RE104 (4-HO-DiPT; Isoprocin Glutarate)  | Phase 1',\n",
       " 'Cluster Headaches |  NYPRG-101 (BOL-148)  | Phase 1',\n",
       " 'Healthy Volunteers  |  GH002 (5-MeO-DMT)  | Phase 1',\n",
       " 'Major Depressive Disorder (MDD)  |  MSP-1014 (Deuterated Psilocybin Prodrug)  | Phase 1',\n",
       " 'Post-traumatic stress disorder (PTSD)|  EMP-01 (MDMA Derivative)  | Phase 1',\n",
       " 'Major Depressive Disorder (MDD)  |  SPL029 (DMT)  | Phase 1',\n",
       " 'Healthy Volunteers  |  SPL028 (Deuterated DMT)  | Phase 1',\n",
       " 'Treatment-resistant depression (TRD)|  VLS-01 (DMT)  | Phase 1',\n",
       " 'Healthy Volunteers  |  BMB-101 (5-HT2C Agonist)  | Phase 1',\n",
       " 'Anxiety Disorders  |  Psilocybin  | Phase 1',\n",
       " 'Migraines  |  NYPRG-101 (BOL-148)  | Phase 1']"
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "text_list3"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "title_df = pd.DataFrame({'Stitle': text_list3})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Stitle</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Post-traumatic stress disorder (PTSD)  |  MDMA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Treatment-resistant depression (TRD)  |  COMP3...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Alcohol use disorder (AUD)  |  Ketamine| Phase 3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Treatment-resistant depression (TRD)| GH001 (5...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Generalized Anxiety Disorder (GAD)  | MM-120 (...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Alcohol Use Disorder (AUD)  |  SYNP-101 (Psilo...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Post-traumatic stress disorder (PTSD)| APEX-25...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Treatment-resistant depression (TRD)|  PCN-101...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Bipolar Disorder II (BDII)  |  GH001 (5-MeO-DM...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Postpartum Depression (PPD)  |  GH001 (5-MeO-D...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Fragile X Syndrome  |  NM-1001 (Psilocybin)  |...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Treatment-resistant depression (TRD)|  BPL-003...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Opioid Withdrawal  | MM-110 (18-MC)  | Phase 2a</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Post-traumatic stress disorder (PTSD)|  MDMA  ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Anorexia nervosa &amp; Binge eating disorder |  MD...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Major Depressive Disorder (MDD)  |  Psilocybin...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Fibromyalgia  |  TRP-8802 (Psilocybin)  | Phas...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Anorexia Nervosa  |  COMP360 (Psilocybin)  | P...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Post-traumatic stress disorder (PTSD)|  COMP36...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Treatment-resistant depression (TRD)|  Psilocy...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Major Depressive Disorder (MDD)  | Spravato (E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Acute Suicidal Ideation and Behaviour  (ASIB) ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Cluster Headaches  |  LSD | Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Generalized Anxiety Disorder (GAD)  |  Psilocy...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>Major Depressive Disorder (MDD)  |  CLE-100 (E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Alcohol Use Disorder (AUD) |  Psilocybin  | Ph...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Obsessive Compulsive Disorder (OCD) |  SYNP-10...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Adjustment Disorder  |  Psilocybin  | Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Alcohol Use Disorder (AUD)  |  BPL-003 (5-MeO-...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Major Depressive Disorder (MDD) |  SPL026 (DMT...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>Attention Deficit Disorder (ADHD)  |  MM120 (L...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>Major Depressive Disorder (MDD)  |  CYB003 (De...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>Opiate Withdrawal Syndrome  |  DMX-1002 (Iboga...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>Major Depressive Disorder (MDD)  |  ELE-101 (P...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>Ischemic Stroke  |  AP-188 (DMT)  | Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>Healthy Volunteers |  BMND01 (DMT)  | Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>Healthy Volunteers  |  Psilocybin  | Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>Autism Spectrum Disorder (ASD)  |  MM-402 (R(-...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>Healthy Volunteers  |  Mescaline  | Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>Healthy Volunteers  |  RE104 (4-HO-DiPT; Isopr...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>Cluster Headaches |  NYPRG-101 (BOL-148)  | Ph...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>Healthy Volunteers  |  GH002 (5-MeO-DMT)  | Ph...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>Major Depressive Disorder (MDD)  |  MSP-1014 (...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>Post-traumatic stress disorder (PTSD)|  EMP-01...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>Major Depressive Disorder (MDD)  |  SPL029 (DM...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>Healthy Volunteers  |  SPL028 (Deuterated DMT)...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>Treatment-resistant depression (TRD)|  VLS-01 ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>Healthy Volunteers  |  BMB-101 (5-HT2C Agonist...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>Anxiety Disorders  |  Psilocybin  | Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>Migraines  |  NYPRG-101 (BOL-148)  | Phase 1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                               Stitle\n",
       "0   Post-traumatic stress disorder (PTSD)  |  MDMA...\n",
       "1   Treatment-resistant depression (TRD)  |  COMP3...\n",
       "2    Alcohol use disorder (AUD)  |  Ketamine| Phase 3\n",
       "3   Treatment-resistant depression (TRD)| GH001 (5...\n",
       "4   Generalized Anxiety Disorder (GAD)  | MM-120 (...\n",
       "5   Alcohol Use Disorder (AUD)  |  SYNP-101 (Psilo...\n",
       "6   Post-traumatic stress disorder (PTSD)| APEX-25...\n",
       "7   Treatment-resistant depression (TRD)|  PCN-101...\n",
       "8   Bipolar Disorder II (BDII)  |  GH001 (5-MeO-DM...\n",
       "9   Postpartum Depression (PPD)  |  GH001 (5-MeO-D...\n",
       "10  Fragile X Syndrome  |  NM-1001 (Psilocybin)  |...\n",
       "11  Treatment-resistant depression (TRD)|  BPL-003...\n",
       "12    Opioid Withdrawal  | MM-110 (18-MC)  | Phase 2a\n",
       "13  Post-traumatic stress disorder (PTSD)|  MDMA  ...\n",
       "14  Anorexia nervosa & Binge eating disorder |  MD...\n",
       "15  Major Depressive Disorder (MDD)  |  Psilocybin...\n",
       "16  Fibromyalgia  |  TRP-8802 (Psilocybin)  | Phas...\n",
       "17  Anorexia Nervosa  |  COMP360 (Psilocybin)  | P...\n",
       "18  Post-traumatic stress disorder (PTSD)|  COMP36...\n",
       "19  Treatment-resistant depression (TRD)|  Psilocy...\n",
       "20  Major Depressive Disorder (MDD)  | Spravato (E...\n",
       "21  Acute Suicidal Ideation and Behaviour  (ASIB) ...\n",
       "22                Cluster Headaches  |  LSD | Phase 2\n",
       "23  Generalized Anxiety Disorder (GAD)  |  Psilocy...\n",
       "24  Major Depressive Disorder (MDD)  |  CLE-100 (E...\n",
       "25  Alcohol Use Disorder (AUD) |  Psilocybin  | Ph...\n",
       "26  Obsessive Compulsive Disorder (OCD) |  SYNP-10...\n",
       "27      Adjustment Disorder  |  Psilocybin  | Phase 2\n",
       "28  Alcohol Use Disorder (AUD)  |  BPL-003 (5-MeO-...\n",
       "29  Major Depressive Disorder (MDD) |  SPL026 (DMT...\n",
       "30  Attention Deficit Disorder (ADHD)  |  MM120 (L...\n",
       "31  Major Depressive Disorder (MDD)  |  CYB003 (De...\n",
       "32  Opiate Withdrawal Syndrome  |  DMX-1002 (Iboga...\n",
       "33  Major Depressive Disorder (MDD)  |  ELE-101 (P...\n",
       "34        Ischemic Stroke  |  AP-188 (DMT)  | Phase 1\n",
       "35      Healthy Volunteers |  BMND01 (DMT)  | Phase 1\n",
       "36       Healthy Volunteers  |  Psilocybin  | Phase 1\n",
       "37  Autism Spectrum Disorder (ASD)  |  MM-402 (R(-...\n",
       "38        Healthy Volunteers  |  Mescaline  | Phase 1\n",
       "39  Healthy Volunteers  |  RE104 (4-HO-DiPT; Isopr...\n",
       "40  Cluster Headaches |  NYPRG-101 (BOL-148)  | Ph...\n",
       "41  Healthy Volunteers  |  GH002 (5-MeO-DMT)  | Ph...\n",
       "42  Major Depressive Disorder (MDD)  |  MSP-1014 (...\n",
       "43  Post-traumatic stress disorder (PTSD)|  EMP-01...\n",
       "44  Major Depressive Disorder (MDD)  |  SPL029 (DM...\n",
       "45  Healthy Volunteers  |  SPL028 (Deuterated DMT)...\n",
       "46  Treatment-resistant depression (TRD)|  VLS-01 ...\n",
       "47  Healthy Volunteers  |  BMB-101 (5-HT2C Agonist...\n",
       "48        Anxiety Disorders  |  Psilocybin  | Phase 1\n",
       "49       Migraines  |  NYPRG-101 (BOL-148)  | Phase 1"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "title_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "title_df['Phase'] = title_df['Stitle'].str.split(r'( Phase \\w+)', expand=True)[1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Stitle</th>\n",
       "      <th>Phase</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Post-traumatic stress disorder (PTSD)  |  MDMA...</td>\n",
       "      <td>Phase 3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Treatment-resistant depression (TRD)  |  COMP3...</td>\n",
       "      <td>Phase 3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Alcohol use disorder (AUD)  |  Ketamine| Phase 3</td>\n",
       "      <td>Phase 3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Treatment-resistant depression (TRD)| GH001 (5...</td>\n",
       "      <td>Phase 2b</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Generalized Anxiety Disorder (GAD)  | MM-120 (...</td>\n",
       "      <td>Phase 2b</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Alcohol Use Disorder (AUD)  |  SYNP-101 (Psilo...</td>\n",
       "      <td>Phase 2b</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Post-traumatic stress disorder (PTSD)| APEX-25...</td>\n",
       "      <td>Phase 2b</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Treatment-resistant depression (TRD)|  PCN-101...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Bipolar Disorder II (BDII)  |  GH001 (5-MeO-DM...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Postpartum Depression (PPD)  |  GH001 (5-MeO-D...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Fragile X Syndrome  |  NM-1001 (Psilocybin)  |...</td>\n",
       "      <td>Phase 2a</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Treatment-resistant depression (TRD)|  BPL-003...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Opioid Withdrawal  | MM-110 (18-MC)  | Phase 2a</td>\n",
       "      <td>Phase 2a</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Post-traumatic stress disorder (PTSD)|  MDMA  ...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Anorexia nervosa &amp; Binge eating disorder |  MD...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Major Depressive Disorder (MDD)  |  Psilocybin...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Fibromyalgia  |  TRP-8802 (Psilocybin)  | Phas...</td>\n",
       "      <td>Phase 2a</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Anorexia Nervosa  |  COMP360 (Psilocybin)  | P...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Post-traumatic stress disorder (PTSD)|  COMP36...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Treatment-resistant depression (TRD)|  Psilocy...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Major Depressive Disorder (MDD)  | Spravato (E...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Acute Suicidal Ideation and Behaviour  (ASIB) ...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Cluster Headaches  |  LSD | Phase 2</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Generalized Anxiety Disorder (GAD)  |  Psilocy...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>Major Depressive Disorder (MDD)  |  CLE-100 (E...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Alcohol Use Disorder (AUD) |  Psilocybin  | Ph...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Obsessive Compulsive Disorder (OCD) |  SYNP-10...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Adjustment Disorder  |  Psilocybin  | Phase 2</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Alcohol Use Disorder (AUD)  |  BPL-003 (5-MeO-...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Major Depressive Disorder (MDD) |  SPL026 (DMT...</td>\n",
       "      <td>Phase 2a</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>Attention Deficit Disorder (ADHD)  |  MM120 (L...</td>\n",
       "      <td>Phase 2a</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>Major Depressive Disorder (MDD)  |  CYB003 (De...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>Opiate Withdrawal Syndrome  |  DMX-1002 (Iboga...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>Major Depressive Disorder (MDD)  |  ELE-101 (P...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>Ischemic Stroke  |  AP-188 (DMT)  | Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>Healthy Volunteers |  BMND01 (DMT)  | Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>Healthy Volunteers  |  Psilocybin  | Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>Autism Spectrum Disorder (ASD)  |  MM-402 (R(-...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>Healthy Volunteers  |  Mescaline  | Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>Healthy Volunteers  |  RE104 (4-HO-DiPT; Isopr...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>Cluster Headaches |  NYPRG-101 (BOL-148)  | Ph...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>Healthy Volunteers  |  GH002 (5-MeO-DMT)  | Ph...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>Major Depressive Disorder (MDD)  |  MSP-1014 (...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>Post-traumatic stress disorder (PTSD)|  EMP-01...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>Major Depressive Disorder (MDD)  |  SPL029 (DM...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>Healthy Volunteers  |  SPL028 (Deuterated DMT)...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>Treatment-resistant depression (TRD)|  VLS-01 ...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>Healthy Volunteers  |  BMB-101 (5-HT2C Agonist...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>Anxiety Disorders  |  Psilocybin  | Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>Migraines  |  NYPRG-101 (BOL-148)  | Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                               Stitle      Phase\n",
       "0   Post-traumatic stress disorder (PTSD)  |  MDMA...    Phase 3\n",
       "1   Treatment-resistant depression (TRD)  |  COMP3...    Phase 3\n",
       "2    Alcohol use disorder (AUD)  |  Ketamine| Phase 3    Phase 3\n",
       "3   Treatment-resistant depression (TRD)| GH001 (5...   Phase 2b\n",
       "4   Generalized Anxiety Disorder (GAD)  | MM-120 (...   Phase 2b\n",
       "5   Alcohol Use Disorder (AUD)  |  SYNP-101 (Psilo...   Phase 2b\n",
       "6   Post-traumatic stress disorder (PTSD)| APEX-25...   Phase 2b\n",
       "7   Treatment-resistant depression (TRD)|  PCN-101...    Phase 2\n",
       "8   Bipolar Disorder II (BDII)  |  GH001 (5-MeO-DM...    Phase 2\n",
       "9   Postpartum Depression (PPD)  |  GH001 (5-MeO-D...    Phase 2\n",
       "10  Fragile X Syndrome  |  NM-1001 (Psilocybin)  |...   Phase 2a\n",
       "11  Treatment-resistant depression (TRD)|  BPL-003...    Phase 2\n",
       "12    Opioid Withdrawal  | MM-110 (18-MC)  | Phase 2a   Phase 2a\n",
       "13  Post-traumatic stress disorder (PTSD)|  MDMA  ...    Phase 2\n",
       "14  Anorexia nervosa & Binge eating disorder |  MD...    Phase 2\n",
       "15  Major Depressive Disorder (MDD)  |  Psilocybin...    Phase 2\n",
       "16  Fibromyalgia  |  TRP-8802 (Psilocybin)  | Phas...   Phase 2a\n",
       "17  Anorexia Nervosa  |  COMP360 (Psilocybin)  | P...    Phase 2\n",
       "18  Post-traumatic stress disorder (PTSD)|  COMP36...    Phase 2\n",
       "19  Treatment-resistant depression (TRD)|  Psilocy...    Phase 2\n",
       "20  Major Depressive Disorder (MDD)  | Spravato (E...    Phase 2\n",
       "21  Acute Suicidal Ideation and Behaviour  (ASIB) ...    Phase 2\n",
       "22                Cluster Headaches  |  LSD | Phase 2    Phase 2\n",
       "23  Generalized Anxiety Disorder (GAD)  |  Psilocy...    Phase 2\n",
       "24  Major Depressive Disorder (MDD)  |  CLE-100 (E...    Phase 2\n",
       "25  Alcohol Use Disorder (AUD) |  Psilocybin  | Ph...    Phase 2\n",
       "26  Obsessive Compulsive Disorder (OCD) |  SYNP-10...    Phase 2\n",
       "27      Adjustment Disorder  |  Psilocybin  | Phase 2    Phase 2\n",
       "28  Alcohol Use Disorder (AUD)  |  BPL-003 (5-MeO-...    Phase 2\n",
       "29  Major Depressive Disorder (MDD) |  SPL026 (DMT...   Phase 2a\n",
       "30  Attention Deficit Disorder (ADHD)  |  MM120 (L...   Phase 2a\n",
       "31  Major Depressive Disorder (MDD)  |  CYB003 (De...    Phase 1\n",
       "32  Opiate Withdrawal Syndrome  |  DMX-1002 (Iboga...    Phase 1\n",
       "33  Major Depressive Disorder (MDD)  |  ELE-101 (P...    Phase 1\n",
       "34        Ischemic Stroke  |  AP-188 (DMT)  | Phase 1    Phase 1\n",
       "35      Healthy Volunteers |  BMND01 (DMT)  | Phase 1    Phase 1\n",
       "36       Healthy Volunteers  |  Psilocybin  | Phase 1    Phase 1\n",
       "37  Autism Spectrum Disorder (ASD)  |  MM-402 (R(-...    Phase 1\n",
       "38        Healthy Volunteers  |  Mescaline  | Phase 1    Phase 1\n",
       "39  Healthy Volunteers  |  RE104 (4-HO-DiPT; Isopr...    Phase 1\n",
       "40  Cluster Headaches |  NYPRG-101 (BOL-148)  | Ph...    Phase 1\n",
       "41  Healthy Volunteers  |  GH002 (5-MeO-DMT)  | Ph...    Phase 1\n",
       "42  Major Depressive Disorder (MDD)  |  MSP-1014 (...    Phase 1\n",
       "43  Post-traumatic stress disorder (PTSD)|  EMP-01...    Phase 1\n",
       "44  Major Depressive Disorder (MDD)  |  SPL029 (DM...    Phase 1\n",
       "45  Healthy Volunteers  |  SPL028 (Deuterated DMT)...    Phase 1\n",
       "46  Treatment-resistant depression (TRD)|  VLS-01 ...    Phase 1\n",
       "47  Healthy Volunteers  |  BMB-101 (5-HT2C Agonist...    Phase 1\n",
       "48        Anxiety Disorders  |  Psilocybin  | Phase 1    Phase 1\n",
       "49       Migraines  |  NYPRG-101 (BOL-148)  | Phase 1    Phase 1"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "title_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [],
   "source": [
    "title_df['Stitle'] = title_df['Stitle'].str.replace(r'(\\| Phase \\w+)', '', regex=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Stitle</th>\n",
       "      <th>Phase</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Post-traumatic stress disorder (PTSD)  |  MDMA</td>\n",
       "      <td>Phase 3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Treatment-resistant depression (TRD)  |  COMP3...</td>\n",
       "      <td>Phase 3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Alcohol use disorder (AUD)  |  Ketamine</td>\n",
       "      <td>Phase 3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Treatment-resistant depression (TRD)| GH001 (5...</td>\n",
       "      <td>Phase 2b</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Generalized Anxiety Disorder (GAD)  | MM-120 (...</td>\n",
       "      <td>Phase 2b</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Alcohol Use Disorder (AUD)  |  SYNP-101 (Psilo...</td>\n",
       "      <td>Phase 2b</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Post-traumatic stress disorder (PTSD)| APEX-25...</td>\n",
       "      <td>Phase 2b</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Treatment-resistant depression (TRD)|  PCN-101...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Bipolar Disorder II (BDII)  |  GH001 (5-MeO-DM...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Postpartum Depression (PPD)  |  GH001 (5-MeO-D...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Fragile X Syndrome  |  NM-1001 (Psilocybin)</td>\n",
       "      <td>Phase 2a</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Treatment-resistant depression (TRD)|  BPL-003...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Opioid Withdrawal  | MM-110 (18-MC)</td>\n",
       "      <td>Phase 2a</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Post-traumatic stress disorder (PTSD)|  MDMA</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Anorexia nervosa &amp; Binge eating disorder |  MD...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Major Depressive Disorder (MDD)  |  Psilocybin</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Fibromyalgia  |  TRP-8802 (Psilocybin)</td>\n",
       "      <td>Phase 2a</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Anorexia Nervosa  |  COMP360 (Psilocybin)</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Post-traumatic stress disorder (PTSD)|  COMP36...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Treatment-resistant depression (TRD)|  Psilocy...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Major Depressive Disorder (MDD)  | Spravato (E...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Acute Suicidal Ideation and Behaviour  (ASIB) ...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Cluster Headaches  |  LSD</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Generalized Anxiety Disorder (GAD)  |  Psilocy...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>Major Depressive Disorder (MDD)  |  CLE-100 (E...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Alcohol Use Disorder (AUD) |  Psilocybin</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Obsessive Compulsive Disorder (OCD) |  SYNP-10...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Adjustment Disorder  |  Psilocybin</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Alcohol Use Disorder (AUD)  |  BPL-003 (5-MeO-...</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Major Depressive Disorder (MDD) |  SPL026 (DMT...</td>\n",
       "      <td>Phase 2a</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>Attention Deficit Disorder (ADHD)  |  MM120 (L...</td>\n",
       "      <td>Phase 2a</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>Major Depressive Disorder (MDD)  |  CYB003 (De...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>Opiate Withdrawal Syndrome  |  DMX-1002 (Iboga...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>Major Depressive Disorder (MDD)  |  ELE-101 (P...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>Ischemic Stroke  |  AP-188 (DMT)</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>Healthy Volunteers |  BMND01 (DMT)</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>Healthy Volunteers  |  Psilocybin</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>Autism Spectrum Disorder (ASD)  |  MM-402 (R(-...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>Healthy Volunteers  |  Mescaline</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>Healthy Volunteers  |  RE104 (4-HO-DiPT; Isopr...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>Cluster Headaches |  NYPRG-101 (BOL-148)</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>Healthy Volunteers  |  GH002 (5-MeO-DMT)</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>Major Depressive Disorder (MDD)  |  MSP-1014 (...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>Post-traumatic stress disorder (PTSD)|  EMP-01...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>Major Depressive Disorder (MDD)  |  SPL029 (DM...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>Healthy Volunteers  |  SPL028 (Deuterated DMT)</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>Treatment-resistant depression (TRD)|  VLS-01 ...</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>Healthy Volunteers  |  BMB-101 (5-HT2C Agonist)</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>Anxiety Disorders  |  Psilocybin</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>Migraines  |  NYPRG-101 (BOL-148)</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                               Stitle      Phase\n",
       "0      Post-traumatic stress disorder (PTSD)  |  MDMA    Phase 3\n",
       "1   Treatment-resistant depression (TRD)  |  COMP3...    Phase 3\n",
       "2             Alcohol use disorder (AUD)  |  Ketamine    Phase 3\n",
       "3   Treatment-resistant depression (TRD)| GH001 (5...   Phase 2b\n",
       "4   Generalized Anxiety Disorder (GAD)  | MM-120 (...   Phase 2b\n",
       "5   Alcohol Use Disorder (AUD)  |  SYNP-101 (Psilo...   Phase 2b\n",
       "6   Post-traumatic stress disorder (PTSD)| APEX-25...   Phase 2b\n",
       "7   Treatment-resistant depression (TRD)|  PCN-101...    Phase 2\n",
       "8   Bipolar Disorder II (BDII)  |  GH001 (5-MeO-DM...    Phase 2\n",
       "9   Postpartum Depression (PPD)  |  GH001 (5-MeO-D...    Phase 2\n",
       "10      Fragile X Syndrome  |  NM-1001 (Psilocybin)     Phase 2a\n",
       "11  Treatment-resistant depression (TRD)|  BPL-003...    Phase 2\n",
       "12              Opioid Withdrawal  | MM-110 (18-MC)     Phase 2a\n",
       "13     Post-traumatic stress disorder (PTSD)|  MDMA      Phase 2\n",
       "14  Anorexia nervosa & Binge eating disorder |  MD...    Phase 2\n",
       "15   Major Depressive Disorder (MDD)  |  Psilocybin      Phase 2\n",
       "16           Fibromyalgia  |  TRP-8802 (Psilocybin)     Phase 2a\n",
       "17        Anorexia Nervosa  |  COMP360 (Psilocybin)      Phase 2\n",
       "18  Post-traumatic stress disorder (PTSD)|  COMP36...    Phase 2\n",
       "19  Treatment-resistant depression (TRD)|  Psilocy...    Phase 2\n",
       "20  Major Depressive Disorder (MDD)  | Spravato (E...    Phase 2\n",
       "21  Acute Suicidal Ideation and Behaviour  (ASIB) ...    Phase 2\n",
       "22                         Cluster Headaches  |  LSD     Phase 2\n",
       "23  Generalized Anxiety Disorder (GAD)  |  Psilocy...    Phase 2\n",
       "24  Major Depressive Disorder (MDD)  |  CLE-100 (E...    Phase 2\n",
       "25         Alcohol Use Disorder (AUD) |  Psilocybin      Phase 2\n",
       "26  Obsessive Compulsive Disorder (OCD) |  SYNP-10...    Phase 2\n",
       "27               Adjustment Disorder  |  Psilocybin      Phase 2\n",
       "28  Alcohol Use Disorder (AUD)  |  BPL-003 (5-MeO-...    Phase 2\n",
       "29  Major Depressive Disorder (MDD) |  SPL026 (DMT...   Phase 2a\n",
       "30  Attention Deficit Disorder (ADHD)  |  MM120 (L...   Phase 2a\n",
       "31  Major Depressive Disorder (MDD)  |  CYB003 (De...    Phase 1\n",
       "32  Opiate Withdrawal Syndrome  |  DMX-1002 (Iboga...    Phase 1\n",
       "33  Major Depressive Disorder (MDD)  |  ELE-101 (P...    Phase 1\n",
       "34                 Ischemic Stroke  |  AP-188 (DMT)      Phase 1\n",
       "35               Healthy Volunteers |  BMND01 (DMT)      Phase 1\n",
       "36                Healthy Volunteers  |  Psilocybin      Phase 1\n",
       "37  Autism Spectrum Disorder (ASD)  |  MM-402 (R(-...    Phase 1\n",
       "38                 Healthy Volunteers  |  Mescaline      Phase 1\n",
       "39  Healthy Volunteers  |  RE104 (4-HO-DiPT; Isopr...    Phase 1\n",
       "40         Cluster Headaches |  NYPRG-101 (BOL-148)      Phase 1\n",
       "41         Healthy Volunteers  |  GH002 (5-MeO-DMT)      Phase 1\n",
       "42  Major Depressive Disorder (MDD)  |  MSP-1014 (...    Phase 1\n",
       "43  Post-traumatic stress disorder (PTSD)|  EMP-01...    Phase 1\n",
       "44  Major Depressive Disorder (MDD)  |  SPL029 (DM...    Phase 1\n",
       "45   Healthy Volunteers  |  SPL028 (Deuterated DMT)      Phase 1\n",
       "46  Treatment-resistant depression (TRD)|  VLS-01 ...    Phase 1\n",
       "47  Healthy Volunteers  |  BMB-101 (5-HT2C Agonist)      Phase 1\n",
       "48                 Anxiety Disorders  |  Psilocybin      Phase 1\n",
       "49                Migraines  |  NYPRG-101 (BOL-148)      Phase 1"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "title_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [],
   "source": [
    "final_tracking= pd.concat([labs_div, title_df], axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Alt Text</th>\n",
       "      <th>Text</th>\n",
       "      <th>Stitle</th>\n",
       "      <th>Phase</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>MAPS PBC</td>\n",
       "      <td>MAPS has completed conducting two Phase 3 tria...</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)  |  MDMA</td>\n",
       "      <td>Phase 3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Compass Pathways</td>\n",
       "      <td>COMP360 is a psilocybin formulation currently ...</td>\n",
       "      <td>Treatment-resistant depression (TRD)  |  COMP3...</td>\n",
       "      <td>Phase 3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Awakn Life Sciences</td>\n",
       "      <td>Awakn is set to evaluate ketamine-assisted psy...</td>\n",
       "      <td>Alcohol use disorder (AUD)  |  Ketamine</td>\n",
       "      <td>Phase 3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>GH Research</td>\n",
       "      <td>GH001 is an inhaled formulation of 5-MeO-DMT, ...</td>\n",
       "      <td>Treatment-resistant depression (TRD)| GH001 (5...</td>\n",
       "      <td>Phase 2b</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>MindMed</td>\n",
       "      <td>MM-120 is a formulation of LSD being evaluated...</td>\n",
       "      <td>Generalized Anxiety Disorder (GAD)  | MM-120 (...</td>\n",
       "      <td>Phase 2b</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>PSYLO</td>\n",
       "      <td>Psylo is currently in the discovery stages of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>Mindstate Design</td>\n",
       "      <td>MSD-101, MSD-102, MSD-103, MSD-104, MSD-105 Di...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>Lusaris Therapeutics</td>\n",
       "      <td>Lusaris is developing a portfolio of new compo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>Beckley Psytech</td>\n",
       "      <td>NCE discovery program.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>Onsero</td>\n",
       "      <td>Onsero is developing a portfolio of unknown 5-...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>88 rows × 4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                 Alt Text                                               Text  \\\n",
       "0                MAPS PBC  MAPS has completed conducting two Phase 3 tria...   \n",
       "1       Compass Pathways   COMP360 is a psilocybin formulation currently ...   \n",
       "2     Awakn Life Sciences  Awakn is set to evaluate ketamine-assisted psy...   \n",
       "3             GH Research  GH001 is an inhaled formulation of 5-MeO-DMT, ...   \n",
       "4                MindMed   MM-120 is a formulation of LSD being evaluated...   \n",
       "..                    ...                                                ...   \n",
       "83                 PSYLO   Psylo is currently in the discovery stages of ...   \n",
       "84       Mindstate Design  MSD-101, MSD-102, MSD-103, MSD-104, MSD-105 Di...   \n",
       "85  Lusaris Therapeutics   Lusaris is developing a portfolio of new compo...   \n",
       "86       Beckley Psytech                              NCE discovery program.   \n",
       "87                Onsero   Onsero is developing a portfolio of unknown 5-...   \n",
       "\n",
       "                                               Stitle      Phase  \n",
       "0      Post-traumatic stress disorder (PTSD)  |  MDMA    Phase 3  \n",
       "1   Treatment-resistant depression (TRD)  |  COMP3...    Phase 3  \n",
       "2             Alcohol use disorder (AUD)  |  Ketamine    Phase 3  \n",
       "3   Treatment-resistant depression (TRD)| GH001 (5...   Phase 2b  \n",
       "4   Generalized Anxiety Disorder (GAD)  | MM-120 (...   Phase 2b  \n",
       "..                                                ...        ...  \n",
       "83                                                NaN        NaN  \n",
       "84                                                NaN        NaN  \n",
       "85                                                NaN        NaN  \n",
       "86                                                NaN        NaN  \n",
       "87                                                NaN        NaN  \n",
       "\n",
       "[88 rows x 4 columns]"
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "final_tracking"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [],
   "source": [
    "final_tracking2 = final_tracking.rename(columns={\"Alt Text\": \"Lab\", \"Text\": \"Study explanation\", 'Stitle':'Study title', 'Phase':'Phase'})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [],
   "source": [
    "final_tracking2.to_csv('./final_tracking.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.12"
  },
  "orig_nbformat": 4,
  "vscode": {
   "interpreter": {
    "hash": "c7f150e609b07d99aad3a4a27bdccca5bb1500101f3d57e0b9abdd6fbb3fce4c"
   }
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
